A cellular model of inflammation for identifying TNF-α synthesis inhibitors by Tweedie, David et al.
A cellular model of inflammation for identifying TNF-α synthesis
inhibitors
David Tweedie1,*, Weiming Luo1, Ryan G. Short1, Arnold Brossi2, Harold W. Holloway1,
Yazhou Li1, Qian-sheng Yu1, and Nigel H. Greig1
1 Drug Design and Development Section, Laboratory of Neurosciences, Intramural Research
Program, National Institute on Aging, Baltimore, MD 21224, USA
2 School of Pharmacy, University of North Carolina, Chapel Hill, NC 27599, USA
Abstract
Neuroinflammation is a common facet of both acute and chronic neurodegenerative conditions,
exemplified by stroke and by Alzheimer’s and Parkinson’s disease, and the presence of elevated
levels of the proinflammatory cytokine, tumor necrosis factor-α (TNF-α) has been documented in
each. Although initial TNF-α generation is associated with a protective compensatory response, its
unregulated chronic elevation is generally detrimental and can drive the disease process. In such
circumstances, therapeutic strategies that can both gain access to the brain and target the production
of TNF-α are predicted to be of clinical benefit. An in vitro mouse macrophage-like cellular screen,
utilizing RAW 264.7 cells, was hence developed to identify novel TNF-α lowering agents
incorporating lipophilic physicochemical characteristics predicted to allow penetration of the blood-
brain barrier. Cultured RAW 264.7 cells exposed to lipopolysaccharide (LPS) induced a rapid,
marked and concentration-dependent cellular release of TNF-α into the cell culture media, which
was readily detected by Enzyme Linked ImmunoSorbent Assay (ELISA). The effects of four
characterized thalidomide-based TNF-α lowering agents were assessed alongside 10 novel
uncharacterized compounds synthesized on the same backbone. One of these new analogs possessed
activity of sufficient magnitude to warrant further investigation. Activity determined in the cellular
model translated to an in vivo rodent model of acute LPS-induced TNF-α elevation. The utility of
the TNF-α cellular assay lies in its simplicity and robust nature, providing a tool for initial
pharmacological screening to allow for the rapid identification novel TNF-α lowering agents.
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1. Introduction
Debilitating dementia related diseases of the central nervous system (CNS) are becoming
progressively prevalent in the aging human population worldwide. Alzheimer’s disease (AD)
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is the most prevalent of these and, according to recent estimates, afflicts some 27 million people
globally. This includes some 5 million Americans, a number that is expected to rise in
forthcoming years. A common feature of AD and numerous neurological disorders is the
involvement of an unregulated inflammatory status of the brain resident macrophage, the
microglial cell (Maccioni et al., 2009; Rogers et al., 2007). A key pro-inflammatory protein
synthesized and released by activated microglial cells is tumor necrosis factor-α (TNF-α)
(Streit et al., 2005, Rogers & Lahiri, 2004). Not surprisingly, the presence of elevated levels
of TNF-α has been documented in many forms of neurodegenerative disease of both chronic
(e.g., AD, Parkinson’s disease, and amyotrophic lateral sclerosis) and acute onset (e.g., stroke
and head trauma) (Tweedie et al., 2007). Recently in the setting of AD, anti-TNF-α therapy
has been reported to provide rapid cognitive improvement in patients using perispinal injection
of Enbrel (Etanercept, Tobincik 2007Etanercept, Tobincik 2008). Enbrel and alike anti-TNF-
α therapeutics currently on the market (e.g., Remicade Infliximab), are large macromolecules
that sequester and clear released TNF-α before it can bind to its receptors; thereby, preventing
TNF-α signaling from taking place. Unfortunately, these proteins possess strictly limited
blood-brain barrier penetrability, making their utility for neurological disorders less than
optimal.
A potentially simpler approach would be to treat patients with small drug-like agents that
combine TNF-α lowering activities with the potential to cross biological membranes, such as
the gastrointestinal tract and blood-brain barrier. Thalidomide (N-α-phthalimidoglutarimide)
possesses such properties through its ability to reduce the rate of synthesis of TNF-α protein
(Moreira et al., 1993) and, consequent to its lipophilicity, is able to readily enter the brain
(Melchert & List, 2007). Unfortunately, the TNF-α lowering activity of thalidomide is not
particularly potent, requiring high doses that are both sedative and associated with adverse
effects (Pillemer et al., 2004). Nevertheless, thalidomide provides a useful backbone to support
the synthesis and development of feasibly more TNF-α potent and better tolerated analogues,
as was successfully achieved with the analogue, lenalidomide (Revlimid), for treatment of
multiple myeloma (Falco et al., 2008; Ocio et al., 2008). Agents such as these may have a
utility in the clinical treatment of several neurodegenerative diseases (Tweedie at al., 2007).
To identify novel TNF-α lowering agents, a robust, rapid and reproducible in vitro macrophage-
like, RAW 264.7 cell model was developed that utilizes an endotoxin, lipopolysaccharide
(LPS). This component of the outer membrane of Gram-negative bacteria binds the CD14/
TLR4/MD2 receptor complex, which promotes the secretion of pro-inflammatory cytokines
in many cell types, but especially macrophage/microglial cells (Bosshart & Heinzelmann,
2007) in both in vitro and in vivo models of inflammation. Herein, we used LPS to stimulate
RAW 264.7 cells to quantify the ability of thalidomide and analogs to lower the levels of
induced TNF-α protein detected in culture media. This was combined with analysis of cell
viability to differentiate a selective reduction in TNF-α synthesis from a non-specific decline
in protein synthesis consequent to drug-induced toxicity. Well-tolerated agents that lower TNF-
α may prove of value in defining the role of CNS microglial-induced TNF-α dependent events
in the progressive nature of several CNS diseases.
2. Materials and Methods
2.1 Basic Culture of RAW 264.7 Cells
RAW 264.7 cells purchased from ATCC (Manassas, VA, USA), were grown in DMEM media
supplemented with 10% FCS, penicillin 100 U/ml and streptomycin 100 μg/ml, were
maintained at 37°C and 5% CO2, and were propagated as described by ATCC guidelines. For
initial studies, different known densities of RAW 264.7 cells (50–800 × 103) were grown in
24 well plates and their viability and basal secretion of TNF-α (ELISA, BD Biosciences, San
Jose, CA) were quantified over a period of 19 hr, initiated 24 hr after seeding. For all subsequent
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experiments, RAW 264.7 cells were seeded at a density of 100,000 cells per well in 24 well
plates. One to two hours prior to the initiation of any pharmacological study, the seeding media
was replaced with fresh media and the cells were allowed to equilibrate at 37°C and 5%
CO2.
2.2 LPS-TNF-α Concentration Effect Study
RAW 264.7 cells were challenged with LPS (SIGMA, serotype 055:B5) at 0.1, 0.3, 0.6, 1, 10,
30 and 60 ng/ml. Each concentration was prepared in sterile saline and applied directly to each
well in a 24 well plate. At 18 to 19 hr following the addition of LPS, conditioned media was
harvested and analyzed for the quantification of secreted TNF-α protein levels or for the
measurement of cell toxicity/proliferation. When cell proliferation was assessed, fresh drug
and LPS free media was added to the wells and the appropriate assay was performed. In a
separate experiment, the effects of a single concentration of LPS were assessed on the time
dependence of the activation of RAW 264.7 cells. Culture media was harvested at 0, 15, 30
and 60 min and then hourly up to 5 hr after the addition of LPS to the cell culture media.
Increases in the levels of TNF-α protein released into media were used as an index of RAW
264.7 cell activation.
2.3 LPS and TNF-α studies
Thalidomide and analogs were prepared in tissue culture grade dimethylsulphoxide (DMSO,
SIGMA). RAW 264.7 cells were pretreated with thalidomide and analogs or vehicle (1:200
dilution) one hour prior to the addition of a single concentration of LPS. As described above,
conditioned media was harvested and used for analysis of secreted TNF-α protein, cellular
toxicity or proliferation. In the current study, the effects of thalidomide and four characterized
thio-thalidomide analogs (Figure 1) were assessed in half-log concentrations ranging from 100
nM to 30 μM. Table 1 indicates the molar ratio and g per ml quantity for thalidomide and
analogs used in this study. An additional series of novel thalidomide analogs (Figure 2) were,
thereafter, assessed for TNF-α lowering activity at 3, 10 and 30μM concentrations.
Thalidomide and analogues were synthesized to a chemical purity of >99.5%, and chemical
characterization was undertaken by a combination of 1H NMR, 13C NMR and GC/MS analyses
(Bruker AC-300 spectrometer (Zhu et al., 2003)), together with elemental analyses (Atlantic
Microlab, Inc., Norcross, GA).
2.4 Cellular Toxicity/Proliferation in Drug Treated RAW 264.7 Cells
Two methods were used to define drug-induced cellular toxicity/proliferation: the lactate
dehydrogenase (LDH) assay is a widely accepted measure of cellular toxicity (Lahiri et al.,
1998), and the CellTiter 96 AQueous One Solution Cell Proliferation Assay (Promega,
Madison, WI) is routinely used as an assay of cell proliferation. Both assays were performed
as recommended by the manufacturer. Changes in cellular health status are determined by use
of indirect measures related to the formation of a colored tetrazolium dye product that can be
measured spectrophotometrically at 490 nm λ An increase in absorbance at 490 nm is indicative
of an elevated release of cellular LDH, consequent to loss of cell membrane viability: a positive
marker of toxicity (LDH assay), or an increase in cell numbers for the cell proliferation assay.
Optical densities (O.D.) were measured after 4 hr incubation at appropriate conditions.
2.5 Acute rodent treatment of LPS-induced TNF-α
Male Fisher 344 rats were anaesthetized (50 mg/kg sodium pentobarbital, 1 ml/kg vol. i.p.)
and the right femoral artery was cannulated for blood sample collection (PE 50 catheter, filled
with heparinized isotonic saline). Rats were pretreated with vehicle, with thalidomide or an
analog at an equimolar concentration of 50 mg per/kg body weight thalidomide (i.p.). LPS (E.
coli, 055:B5, SIGMA 1 mg/kg, i.p.) was administered one hour thereafter, and serial blood
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samples were collected over a subsequent 4 hr period. Cerebrospinal fluid (CSF) was
withdrawn from the cisterna magna at the final time point. Plasma was derived immediately
after collection (centrifugation: 8,000 G × 5 min), which together with CSF, was analyzed for
TNF-α by ELISA.
2.6 Statistical analyses
Data throughout is expressed as means ± standard errors, with the number (n) of studies
performed in parentheses. Statistical comparisons with controls and between treatments were
undertaken by Dunnett’s T-test, with appropriate Bonferroni corrections for multiple
comparisons as required (GraphPad InStat Version 3.05). P values of <0.05 are considered to
be of statistical significance and specific values are provided within both the Figures and text.
3. Results
3.1 RAW 264.7 cell density and basal TNF-α
To define optimal growing conditions for RAW 264.7 cells, different cell densities were seeded
into 24 well plates and equilibrated for 24 hr. Thereafter, measures of cell viability were
quantified over the subsequent 19 hr. All cultures appeared healthy but as illustrated in Figure
3A, those with cell densities of ≥ 400 ×103 were associated with elevated levels of LDH, in
comparison to both cell free media and cell densities of ≤200. Secreted basal TNF-α levels
related to each cell density are shown in Figure 3B, and correlated positively with cell number
(log concentration vs. TNF-α levels: r2= 0.95). Based on these studies, a cell density of 100 ×
103 was utilized in subsequent work.
3.2 LPS-TNF-α Concentration Dependence
Exposing RAW 264.7 cells to increasing concentrations of LPS induced a significant
concentration-dependent elevation in secreted TNF-α levels in culture media (Figure 4A). A
linear relationship was evident between the levels of secreted TNF-α protein and the
concentration of LPS between 0.1 and 1 ng/ml administered (r2=0.86), with an approximate
~240-fold increase over baseline control TNF-α protein levels induced by 1 ng/ml LPS. TNF-
α protein levels were maximally elevated 260-fold at the highest LPS concentration studied
(60 ng/ml). The amount of protein secreted peaked and remained constant from 10 to 60 ng/
ml LPS (TNF-α levels were: 10,775±760 pg/ml and 10,500±750 pg/ml, for 10 and 60 ng/ml,
respectively; both P<0.0001 vs. control, n=5). In contrast, increasing concentrations of LPS
had minor effects on RAW 264.7 cellular health, as determined by LDH assay, with
insignificant changes in optical density for the tetrazolium dye product that are indicative of
no altered LDH secretion into the culture media (data not shown). Indeed, only at the highest
concentrations of LPS used were small non-significant changes in the LDH levels determined.
The time course for the LPS-induced increase in secreted TNF-α protein levels is presented in
Figure 4B following a submaximal LPS challenge (0.6 ng/ml), which was used in subsequent
studies. Secreted TNF-α protein levels were not significantly different from control values at
15 min after LPS administration; but were significantly elevated 30 min post exposure and
thereafter (TNF-α protein levels were 56±5 and 117±8 pg/ml at 0 and 30 min, respectively,
P=0.003, both n=3).
3.3 LPS-induced TNF-α Lowering Studies
Initial studies utilized DMSO to dissolve thalidomide and analogs at a final dilution of 1:100
in culture media. However, this amount of DMSO proved to be slightly toxic to RAW 264.7
cells, causing a small but significant attenuation in the levels of secreted TNF-α protein detected
in their media. Specifically, DMSO 1:100 media dilution reduced levels from 8,675±345 pg/
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ml to 7,265±365 pg/ml (P=0.012, n=10), some 16.25%. On further investigation, this DMSO
dilution was determined to induce low but, nevertheless, significant, cellular toxicity: the LDH
assay displayed an increase of 192±18% (P=0.0005, n=5), and MTS assay displayed a
reduction of 10.2±2% (P=0.003, n=5). Through subsequent experimentation, a 1:200 dilution
of DMSO in media proved sufficient to solublize thalidomide and analogs without invoking a
detectable cytotoxic response, as monitored by the LDH and cell proliferation assays. Hence,
all subsequent pharmacological studies were performed using DMSO at a 1:200 media dilution.
Under these optimized conditions, thalidomide displayed negligible TNF-α lowering activity
at the concentrations studied. Specifically, 30 μM thalidomide led to a small, insignificant
reduction in TNF-α protein levels (89±6% of control levels), without detectable changes in the
LDH cell proliferation assays (data not shown). Pretreatment with a lower thalidomide dose,
however, led to an insignificant elevation of TNF-α protein levels: 1μM thalidomide elevated
levels to 164±25% of control (P=0.237). On the contrary, several thiothalidomides possessed
TNF-α lowering action that proved more potent than equimolar thalidomide (Figure 5).
Specifically, dithioglutarimide and 3,’6-dithiothalidomide reduced TNF-α levels at
concentrations greater than 3μM. 3, ’2,’6-Trithiothalidomide and 3,’6-dithiopthalimide,
likewise, displayed TNF-α inhibition properties at similar concentrations, but these were
associated with evidence of cellular stress, as marked by elevations (albeit insignificant) in the
LDH assay and reductions in the cell proliferation assay (data not shown). Statistically
significant levels of cellular stress were detected at the highest concentrations of these
compounds (10 and 30 μM). Of the 10 newly synthesized thalidomide analogues (A1–10),
several possessed TNF-α protein lowering properties, which ranged from as little as 8% (analog
A4) up to a 38% reduction (A10). Two agents, in particular, displayed classical concentration-
dependent effects on TNF-α levels while one possessed potent TNF-α lowering properties with
no obvious concentration dependence at those assessed in the present study (compound A10,
Figure 6). A summary of TNF-α activity relative to cytotoxic properties of the agents at
30μM is provided in Table 2.
To assess the translational validity of the cellular assay, in vivo studies were undertaken in rats
administered LPS to induce elevated systemic levels of TNF-α and assess whether or not these
could be lowered by a thalidomide analog determined to possess activity in the cellular screen.
Plasma TNF-α rose from an initially imperceptible level to 45,000 pg/ml by 90 min, it reached
a plateau at 120 min and declined to 8,000 pg/ml by 4 hr. As illustrated in Figure 7, thalidomide
and more potently, dithioglutarimide, lowered plasma TNF-α levels in a time-dependent
manner. By contrast, CSF levels of TNF-α were significantly lowered by dithioglutarimide,
but not thalidomide (Figure 8).
4. Discussion
Herein, we describe an in vitro RAW 264.7 cellular model with the capacity to be used as a
pharmacological screen for novel anti-inflammatory agents that lower the generation of TNF-
α Stimulation of RAW 264.7 cells with the potent immune cell activator, LPS, induced a
marked increase of TNF-α protein release into cell culture media. Prior studies utilizing RAW
264.7 cells consistently demonstrate their ability to synthesize and release a host of markers
of inflammation (Nakao et al., 2008; McClain et al., 2002) and, hence, these cells have proven
a valuable research tool for researchers studying pathological and physiological inflammation
in disease.
In our hands, we employed a RAW 264.7 cell in vitro system to generate a rapid, reproducible
model of inflammation to evaluate pharmacological agents predicted to reduce the levels of
secreted TNF-α protein in culture media. Under our optimized culturing conditions we
demonstrated that the effects of LPS on the RAW 264.7 cells were not associated with cellular
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toxicity. This is critical feature for any cell-based model when conducting pharmacological
research to identify novel drug candidates, which may or may not possess inherent cellular
toxicological properties (Jones & Diamond, 2007; Schinazi et al., 1999). In order to maximize
the detection of the biological window of action of novel thalidomide analogs, we challenged
the RAW 264.7 cells to a sub-maximal dose of LPS where the biological response for TNF-
α appeared to be on the linear part of the LPS concentration/response curve. When comparing
thiothalidomide analog data obtained from this RAW 264.7 cell model with a prior study the
findings were in accord with regard to anti-TNF-α activity and cell toxicity as determined in
freshly prepared human peripheral blood mononuclear cells (PBMCs) (Zhu et al., 2003). At
low concentrations, thalidomide appeared to elevate TNF-α levels, which is likewise in accord
with prior studies (Shannon & Sandoval, 1996). By contrast, all previously characterized thio-
thalidomide analogues effectively lowered TNF-α protein levels in cell culture in a
concentration-dependent manner. Dithioglutarimide, was chosen as a representative of these
to assess translation from cell culture to animals, as it demonstrated moderate TNF-α lowering
action in culture without inducing cellular stress. In animals, unlike thalidomide that
ineffectively altered TNF-α in RAW 264.7 cells and only moderately (less than 50%) lowered
LPS-induced plasma TNF-α levels at 120 min alone, dithioglutarimide substantially lowered
LPS-induced plasma (up to 85%) over an extended period and entirely inhibited any rise in
CSF TNF-α levels in rat (Figures 7 and 8); thereby suggesting that reductions observed in the
cellular assay are of in vivo biological relevance.
The use of RAW 264.7 cells as an in vitro model to study the actions of inflammation on cellular
processes or to identify novel anti-inflammatory agents is becoming more widespread as
evidenced by the abundance of scientific articles published over the last 5 years. Prior to the
establishment of monocyte-macrophage cell-lines (RAW 264.67 cells and others), researchers
were forced to use purified PBMCs. The nature of obtaining these raw materials for use in
pharmacological experiments has several disadvantages. Namely, this type of study is
dependent upon obtaining a regular supply of healthy human blood where the whole blood is
typically subjected to a series of manipulations to purify the white blood cells. Also using
whole blood from different volunteers with different health statuses (i.e., one volunteer may
suffer from allergies and another may not) may well introduce an uncontrollable degree of
variability into pharmacological and physiological markers. In contrast to this, a major
advantage of using a cell line model, such as RAW 264.7 cells as described in this study, is
the highly reproducible nature of the biological response of the cells to immune cell activators,
such as LPS. The utility of a reproducible in vitro RAW 264.7 cell model will allow for a
greater consistency in studying the role both inflammation or anti-inflammatory agents in
disease models and perhaps a more rapid turnover of screened novel anti-inflammatory
pharmacological tools or medicines.
Based on the validation of the RAW 264.7 cellular model by our prior cell-based studies with
PBMCs and translation to a rodent model, we proceeded to assess the potential anti-TNF-α
effects of 10 novel thalidomide based analogs. Of the agents thus far studied, one demonstrated
sufficient potency and lack of cellular toxicity to warrant characterization in animal studies.
Our ongoing cellular and in vivo studies continue to indicate that TNF-α lowering compounds
based on the backbone of thalidomide hold promise as therapeutics for a range of
neurodegenerative conditions, as well as for peripheral autoimmune disease. The continued
design and synthesis of novel thalidomide-based compounds to optimize their pharmacological
actions combined with the described RAW 264.7 LPS model as a primary screen is being
undertaken to test this premise.
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Chemical structures of thalidomide (C log D −0.83) and thiothalidomide analogs. The two
hetrocyclic components that comprise thalidomide were isolated and subjected to specific
thionation reactions to provide dithiopthalimide and dithioglutarimide (C log D 0.72 and −0.54,
respectively). The intact thalidomide pharmacophore was subjected to controlled thionation
reactions to generate the agents 3, 6′-dithiothalidomide and 3, 2′, 6′-trithiothalidomide (C log
D −0.86 and −0.30, respectively).
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The structure of thalidomide and a series of novel thalidomide analogs are shown. The intact
thalidomide pharmacophore underwent a series of medicinal chemistry modifications and the
presented analogs were synthesized and characterized for anti-TNF-α activity.
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Optimization of RAW 264.7 cells in culture. Panel A depicts the relationship between seeded
cell density and viability: increasing cell densities (50 – 800 × 103) were seeded in 24 well
plates and equilibrated (24 hr); 19 hr thereafter, cell viability (n=4) was determined by LDH
assay and compared to cell free media (***P<0.001). Additionally, cell viabilities of 400 and
800 ×103 densities were significantly different from seeded densities of 50 – 200 ×103 cells
(P<0.001, Bonferroni t-test). Panel B shows the relationship between cell density and basal
TNF-α generation: the levels of TNF-α associated with cells described in Panel A were
quantified 19 hr following their equilibration. *P<0.05 was considered statistically significant
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(** P<0.01, *** P<0.001, Dunnett’s t-test) compared to a density of 100 × 103 cells, which
was chosen for all subsequent studies.
Tweedie et al. Page 12














LPS induced a rapid significant elevation in released TNF-α protein by RAW 264.7 cells into
culture media. Panel A represents the LPS dose/response effect: cells were exposed to LPS
for 19 hr and TNF-α levels were analyzed in media samples. All LPS concentrations induced
a significant elevation in secreted TNF-α protein. Panel B displays the time-course of TNF-
α protein release into culture media following LPS (0.6 ng/ml) challenge. A Dunnett’s t-test
was performed and *P<0.05 was considered statistically significant (** P<0.01, *** P<0.001,
n=3–7) compared to no LPS in panel A, and zero time in panel B.
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Effects of thiothalidomide analog pretreatment on the generation of LPS-induced TNF-α
protein levels in RAW 264.7 cells. Drug concentrations less than 1 μM had no TNF-α effects
on LPS treated RAW 264.7 cells (data not shown). Only at concentrations above 10 μM were
there marked reductions in the levels of TNF-α protein detected in culture media (n ≤2). A
Dunnett’s t-test was performed and *P<0.05 was considered statistically significant (**
P<0.01, *** P<0.001).
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The effects of two representative novel thalidomide analogs on the synthesis and release of
LPS induced TNF-α protein levels are presented. Analog A4 possessed modest effects upon
the synthesis and release of TNF-α protein into the cell culture media. A10 possessed significant
TNF-α lowering effects, but failed to display a classical dose-response effect within the
concentrations studied. A Dunnett’s t test was performed and *P<0.05 was statistically
significant (** P<0.01, *** P<0.001), n = 3.
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In vivo effects of thalidomide and analog on LPS-induced plasma TNF-α protein levels in
rodent. Rats were pretreated with vehicle, with thalidomide (50 mg per/kg body weight) or
dithioglutarimide (28 mg per/kg body weight, equimolar to 50 mg per/kg body weight
thalidomide, i.p.). LPS (1 mg/kg, i.p.) was administered one hour thereafter, and serial blood
samples were collected for analysis of plasma TNF-α. Data are expressed as the % change from
LPS-vehicle treated values. A one sample t-test was performed on percentage change from the
LPS-vehicle group, *P values ≤ 0.05 are statistically significant (** P<0.01, *** P<0.001)
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In vivo effects of vehicle, thalidomide and analog on LPS-induced changes in CSF TNF-α
protein levels in rodents. Whereas dithioglutarimide lowered LPS-elevated CSF levels of TNF-
α (P=0.003, one sample t-test), equimolar thalidomide was without significant effect (P>0.05).
CSF TNF-α levels were determined at 4 hr from rats described in Figure 7, and compared to
‘pure controls’ – specifically, entirely naive animals that were unchallenged by LPS,
thalidomide or analog.
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